CD38-LIN-rhodamine'"" phenotype and characteristic biologic properties, including quiescence during normal steady-state hematopoiesis, high proliferative potential, and the ability to self-renew or to differentiate into various hematopoietic lineages."4
HE HEMATOPOIETIC compartment of human bone marrow represents a highly heterogenous population of cells at various stages of differentiation. The most primitive of these cells are stem cells that are responsible for the maintenance of hematopoiesis throughout the lifetime of an individual. Hematopoietic stem cells are unique cells which possess a CD34h' Thy-1 + CD38-LIN-rhodamine'"" phenotype and characteristic biologic properties, including quiescence during normal steady-state hematopoiesis, high proliferative potential, and the ability to self-renew or to differentiate into various hematopoietic lineages." 4 The development of mature hematopoietic cells from stem cells via lineage-committed progenitor cells is a complex process that is regulated at multiple levels of cell differentiation. One of the key mechanisms involved in this regulation is apoptosis (programmed cell death). This mechanism may be spontaneously initiated in cells in the absence of an essential growth factor or it may be triggered by specific extracellular signals delivered by cell surface receptors.s The known membrane molecules transducing apoptosis-initiating signals in hematopoietic cells include the T-cell receptor on thymocytes,6 the Ig receptor on B cells,' and molecules which are members of the tumor necrosis factor (TNF) receptor superfamily, such as TNF receptor, Fas/APO-1, and CD30. * We have recently found that another surface molecule, CD43, is involved in the induction of apoptosis of hematopoietic cells in vitro.' CD43 (leukosialin, sialophorin, the major sialoglycoprotein of leukocytes), broadly expressed on hematopoietic cells, is a highly sialylated mucin-like molecule with a unique primary structure.'" The aberrant expression of CD43 has been identified in patients with the X chromosome-linked immunodeficiency disorder, WiskottAldrich syndrome.''.'* The transmembrane and cytoplasmic domains of CD43 are highly conserved across various species."-I6 Therefore, these domains may participate in mem- brane/intracellular signalling involved in the regulation of critical hematopoietic events. Thus far, CD43 has been shown to deliver signals leading to T-cell proliferation," as well as monocyte" and neutrophil" homotypic aggregation. In addition, it has recently been speculated that CD43 may also participate in the development of acquired immunodeficiency syndrome (AIDS)-related immunodeficiency, because anti-CD43 autoantibodies have been detected in human immunodeficiency virus (H1V)-infected patients.'" However, the precise function of CD43 remains unknown.
We have found that an anti-CD43 monoclonal antibody (MoAb) induces apoptosis of primitive human hematopoietic cells that express CD34 at a high density on the cell surface, but lack markers of individual hematopoietic lineages (CD34h' LIN-cells).' This process results in a 90% inhibition of cytokine-induced proliferation of CD34h' LIN-cells after 12 days of culture. The induction of programmed cell death via CD43 operates at the single-cell level and requires proliferation-inducing cytokines and cross-linking of surface CD43. However, not all cells within the CD34hi LIN-population respond to stimulation via CD43 by apoptosis. A minor population of cells, capable of extensive proliferation in long-term stromal cell-free liquid cultures, consistently survives the anti-CD43 MoAb treatment. In the present study, this surviving population is shown to be enriched for quiescent cells with stem cell characteristics, indicating that these cells are resistant to anti-CD43 MoAb-induced programmed cell death.
from Becton Dickinson (San Jose, CA). JCI59-FITC (glycophorin) was purchased from AMAC Inc (Westbrook, ME).
Cytokines. Human recombinant cytokines including c-kit ligand and erythropoietin purchased from R & D Systems (Minneapolis, MN), as well as leukemia inhibitory factor, interleukin-3 (L-3), IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF) provided by Sandoz Inc (Basel, Switzerland) were used. c-kit ligand and leukemia inhibitory factor were used at a concentration of 50 ng/mL; IL-3, IL-6, and GM-CSF were used at 10 ng/mL; the dose of erythropoietin used was 2 U/mL, if not stated otherwise.
Cell culture medium. Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal calf serum (FCS; Hyclone Laboratories, Logan, UT), penicillin (50 UlmL), streptomycin (50 pg/mL), 2 mmoVL L-glutamine, and 10 pmoVL a-thioglycerol was used, if not stated otherwise.
Isolation of cells. Bone marrow samples were aspirated from healthy adults after informed consent was obtained according to guidelines established by the Declaration of Helsinki. Mononuclear cells were first isolated from these aspirates by density gradient sedimentation using Ficoll-Paque (Pharmacia LKB, Uppsala, Sweden). Next, CD34+ cells were isolated from the mononuclear cell population using the Ceprate LC34-biotin kit (CellPro Inc, Bothell, WA). The purity of CD34' cells eluted from the columns ranged from 75 to 90%. These cells were resuspended in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.2% human immune globulin (Gamimmune N; Miles Inc, Elkhart, IN) and incubated for 15 minutes. The cells were then stained with F(ab'), fragments of anti-CD34 MoAb labeled with sulphorhodamine and MoAbs recognizing markers associated with individual hematopoietic lineages labeled with FITC. The lineage MoAb panel included MoAbs against CD2, CD19, CD14, CD15, CD16, and glycophorin. Propidium iodide (1 pg/mL) was added to each sample to exclude dead cells. The stained cells were sorted on a FACStar (Becton Dickinson, San Jose, CA) and gated for low side light scatter, propidium iodide-sulphorhodaminehigh FITC cells. Cells stained with isotype-matched irrelevant MoAbs were used as a negative control. To isolate CD34hl Thy-l+ LIP-and CD34h' Thy-l-LII" cells, anti-Thy-l-PE was included in the MoAb staining cocktail. The punty of CD34h' LIN-, CD34h' Thy-]+ LIN-, and CD34h' Thy-l-LIN-cells after reanalysis was greater than 90%, 72% to 95%. and 80% to 92%, respectively.
Immuno-staining andflopow cytometry. Cells preincubated for 15 minutes with PBS containing 1% BSA and 0.2% human immune globulin were stained with MoAbs directly conjugated with fluorochromes. After washing, the cells were resuspended in PBS/BSA containing propidium iodide (1 pg/mL) and analyzed by flow cytometry using a FACstar or FACScan (Becton Dickinson).
Immobilization Hematopoietic progenitor cell assay. Cells were resuspended in IMDM containing 30% FCS, 1% BSA, 0.1 mmoVL 2-mercaptoethanol, 2 mmoVL L-glutamine, 2% methylcellulose, c-kit ligand (25 ng/mL), IL-3, GM-CSF, and erythropoietin and then plated in plastic 35-mm tissue culture dishes. After 14 days of culture at 37°C. hematopoietic colonies were enumerated using an inverted light microscope.
PKH26 cell membrane labeling. Cells were labeled with PKH26 using the PKH26 red fluorescent general cell linker kit (Sigma, St Louis, MO). Cells (4 X lo5) were washed with serum-free medium and resuspended in 250 pL of a diluent provided in the kit. Next, the cell suspension was mixed 1:l with the diluent containing 4 pmol/L PKH26 and then incubated for 5 minutes at room temperature. The labeling reaction was stopped by adding 500 pL of FCS. After 1 minute of incubation at room temperature, cells were washed and resuspended in the culture medium.
SCID-hu bone assay. SCID-hu mice were constructed as previously described." Briefly, pieces of human fetal bones obtained in compliance with state and federal regulations were subcutaneously implanted in 6-to 8-week-old homozygous C.B-17 scid'scid (SCID) mice bred under specific pathogen-free conditions. After 8 weeks, mice with vascularized grafts received a single dose (400 rad) of whole body irradiation from a "'Cesium source (JL Shepherd and Associates, San Fernando, CA). Human HLA-mismatched donor cells were injected into the bone grafts. The bone grafts were removed after 8 weeks after cell injection from killed mice and the cellular content of the grafts was harvested by flushing with PBS containing 0.2% BSA. After red blood cell lysis with PBS containing 0.83% ammonium chloride, the harvested cells were washed in PBS/ BSA and stained with the MoAb recognizing donor HLA conjugated with FITC in combination with MoAbs recognizing pan HLA, CD34, CD19, and CD33, conjugated with PE. Finally, the immuno-stained cells were analyzed by flow cytometry. Noninjected grafts were used as a negative control. Injected grafts containing greater than 1% cells expressing the donor HLA were scored as positive.
Cobblestone area-forming cell (CAFC) assay. Human cells were cultured on a pre-established monolayer of SySl murine bone marrow stromal cells, as previously des~ribed.'.~.'~ Briefly, fractions of MoAb-treated cells derived from CD34'" LIN-cells were plated on top of the confluent SySl monolayers at limiting dilution (equivalents of MoAh-treated cells derived from 100 to 0.78 CD34h' LINcells were plated per well, 12 wells per cell concentration) in medium (1:l IMDMMPMI) containing 10% FCS, penicillin (50 UlmL), streptomycin (50 pg/mL), 2 m m o K glutamine, 1 mmoVL sodium pyruvate (JRH Biosciences, Lenexa, KS), 0.1 mmoVL 2-mercaptoethanol (Sigma), leukemia inhibitory factor (50 ng/mL), and IL-6 (10 ng/mL). Cultures were fed weekly with the same medium. After 5 weeks, the cultures were scored for the presence of tightly formed clusters of greater than 50 refractile cells (cobblestone areas). Linear regression analysis was used to determine the frequencies of CAFC.24
Long-term stromal cell-free liquid cultures. Cells (0.5 to 1 X 104/well) were plated in 48-well tissue culture plates coated with MoAbs and cultured in the presence of c-kit ligand, IL-3, and IL-6. After 14 days, cells were quantitatively transferred into 24-well plates and cultured for additional 6 weeks in the presence of c-kit ligand, IL-3, and IL-6. The cultures were supplied with cytokines twice weekly and were regularly depopulated to maintain a cell concentration less than 106/mL. LOG RED FLUORESCENCE MEM-S9 anti-CD43 MoAb, c-kit ligand, and IL-3 for 7 days. This MoAb induced cell death in the CD34h' LIN-cell population (Fig 1 A) , as previously described.' However, a minor population of cells refractory to this mechanism consistently survived the anti-CD43 MoAb treatment ( Table I) . To characterize this surviving population, anti-CD43 MoAb-treated cells were harvested and the surface expression of CD34, CD14, and CD1 S was analyzed. The expression of CD14 and CD15 was examined as a measure of myeloid cell differentiation. The population of cells surviving exposure to anti-CD43 MoAb contained a significantly higher percentage of CD34' cells (42%) in comparison with the control AFP-OI MoAb-treated population (1 6%, Fig 2) . In contrast, the control population contained more differentiated cells expressing CD14 andor CD15 (S6%), as compared with the anti-CD43 MoAb-treated population (21%). Thus, the population of cells resistant to CD43-mediated cell death is enriched for primitive cells expressing CD34, but not CD14 or CD15.
RESULTS

The population
To evaluate whether the sensitivity of CD34hi LIN-cells to apoptosis triggered via CD43 is related to their proliferation status, the effect of immobilized anti-CD43 MoAb on (Fig 3) .
Population of cells refractory to CD43-mediated apoptosis is enriched for CAFCs. To examine whether anti-CD43 MoAb-mediated cell death affects both HPCs and more primitive CAFC, CD34hi LIN-cells were cultured in the presence of immobilized anti-CD43 or control MoAb, c-kit ligand, and IL-3 for 7 days. Identical fractions of harvested MoAb-treated cell populations were then analyzed for the presence of assayable HPCs in methylcellulose assay and for CAFCs in stromal cell-dependent coculture assay. The population of cells cultured in the presence of anti-CD43 MoAb was virtually depleted of HPCs; less than 10% of HPCs survived exposure to anti-CD43 MoAb as compared with the control MoAb-treated cells (Table 2) Table l ) . In contrast, the average frequency of CAFCs in the anti-CD43 MoAb-treated population related to the input CD34h' LIN-cell population was 1/60, which represents 42% of the CAFCs frequency found in the control MoAb-treated population (Table 2) . Because the number of cells surviving exposure to anti-CD43 MoAb was significantly lower (=6%) than the number of control MoAb-treated cells (compare with Table I ) and because identical fractions of MoAb-treated cell cultures were analyzed in the CAFC assay, the population of cells refractory to CD43-mediated cell death was enriched (*7-fold) for CAFCs, as compared with the control MoAb-treated population.
Cells refractoq to CD43-mediated apoptosis engraji in human hone implants in SCID mice. To examine whether the cells surviving anti-CD43 MoAb treatment have the potential to engraft in vivo, CD34hi LIN-cells were cultured for 7 days in liquid culture in the presence of immobilized anti-CD43 MoAb, c-kit ligand, and IL-3 and then injected into human bone grafts implanted in SCID mice (SCID-hu bone). The human bone grafts removed 8 weeks after cell injection were analyzed for donor cell content by flow cytometry. The population of cells resistant to CD43-mediated cell death contained cells that engraft in SCID-hu bone (Table 3); cells derived from liquid cultures initiated with as The results of one representative experiment of four FSC LOG RED FLUORESCENCE are shown.
few as I O4 CD34hi LIN-cells repopulated the bone implants. In addition, CD34', CD19' (B lymphoid) and CD33' (myeloid) cells derived from donor cells treated with anti-CD43 MoAb were recovered from the grafts (Fig 4) . The cells refractory to CD43-mediated cell death thus have the potential to repopulate SCID-hu bone and to maintain a population of primitive CD34' progenitor cells. Moreover, these marrow repopulating cells have the capacity to differentiate into both lymphoid and myeloid cells in vivo.
Cells resistant to CD43-mediated cell death have n high prol$erative potential. The CD34hi LIN-cell population consists of two subpopulations that differ from each other by the expression of Thy-l (Fig 5) . The subpopulation of cells expressing Thy-l contains more primitive cells, including stem cells, as compared with the Thy-I-cell population.'.' (It should be noted that Thy-l is expressed only on CD34hi, but not CD34 cells [Fig S ] . ) To examine whether the CD34h' Thy-1 + LIN-and CD34h' Thy-1 LIN-cell populations respond differently to CD43-mediated stimulation, the effect of anti-CD43 MoAb on the proliferation of these cells was examined in long-term stromal cell-free liquid culture. CD34hi Thy-l + proliferative potential, reaching a maximum cell expansion after 5 to 7 weeks of culture, as compared with CD34hi Thy-1-LIW cells (Fig 6, negative control (Fig 1B) . However, after 3 weeks of culture, anti-CD43 MoAb-treated CD34' Thy-l+ LII-cells began to proliferate. After 5 to 7 weeks, these proliferating cells expanded 3.5 X lo4 fold in average, as related to the initial number of cells seeded in the plate (Table 4 ). In contrast, the proliferation of CD34h' Thy-l-LIN-cells was suppressed by the anti-CD43 MoAb. Thus, a population of CD34hi Thy-l+ LIN-cells with a high proliferative potential is refractory to anti-CD43 MoAb-induced apoptosis.
LIN-cells have a significantly higher
S u~a c e expression of CD43 on CD34hi Thy-l+ LIN-cells. To examine whether the absence of CD43 on the cells originating from the CD34hi Thy-l+ LIP-cell population is responsible for their resistance to anti-CD43 MoAb-mediated apoptosis, the expression of CD43 on freshly isolated CD34hi Thy-l+ LIN-cells was analyzed. All CD34hi Thy-l+ LINcells express CD43 at a high density (Fig 5) . In contrast, the CD34+ Thy-l-LIP-population consists of two subpopulations of cells with CD34hi CD43hi and CD34"" CD43"" phenotypes.
DISCUSSION
The anti-CD43 MoAb MEM-59 induces apoptosis of cytokine-activated CD34hi LIN-cells, as detected by terminal deoxynucleotidyl transferase assay.' Here, CD43-mediated apoptosis is shown to preferentially affect dividing progenitor cells present in this population. In contrast, a minor population of primitive quiescent CD34h' LW-cells (<IO% as compared with the control population) consistently survives anti-CD43 MoAb treatment. These surviving cells are enriched for CAFCs (=7"fold) as compared with the control MoAb-treated cell population (the CAFC assay used here to quantitatively analyze the presence of stem cells was previously shown to well correlate with the long-term culture initiating cell assay).25 In addition, the cells resistant to CD43-mediated apoptosis (1) repopulate human fetal bone fragments implanted in SCID mice giving rise to both myeloid and lymphoid cells (engraftment of primitive hematopoietic progenitor cells in SCID-hu bone assay has been shown to correlate with stem cell a~t i v i t y~,~,~~*~~) , (2) originate from the CD34hi Thy-l+ LIN-stem cell-containing population, and (3) have a high proliferative capacity in stromal cell-free liquid culture. This indicates that CD34hi LIN-cells * Period of culture after which maximum cell expansion was obt Cell numbers were calculated as described in the legend to Fig 6. tained.
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The reason for the ability of stem cells to survive exposure to anti-CD43 MoAb is currently unknown. The absence of CD43 on the surface of these cells cannot account for this phenomenon, because all CD34h' Thy-l + LIN-cells express CD43 at a high density. A more likely possibility is that the induction of apoptosis of primitive hematopoietic cells via CD43 is dependent on their proliferative status. Thus, only proliferating CD34h' LIN-cells may undergo this mechanism. In contrast, quiescent stem cells, which are believed to require a longer period of time to begin proliferating in response to cytokines as compared with progenitor cells, survive anti-CD43 MoAb-treatment. The experiments with PKH26-labeled cells together with our previous finding indicating that CD43-dependent apoptosis is initiated only in cytokine-activated, but not resting progenitor cells' support this hypothesis. In addition, a similar mechanism of cell proliferation-dependent apoptosis of bone marrow CD34+ cells, induced by a chemotherapeutic agent, 5-fluorouracil, has been de~cribed.'~ Potential differences in CD43 signalling pathways in stem cells and progenitor cells may provide an alternative explanation of stem cell resistance to CD43-mediated apoptosis. Such an idea is not unprecedented, because the stimulation of different hematopoietic cell populations via CD43 has been shown to elicit distinct cellular responses. For example, in T cells, anti-CD43 MoAbs induce cell proliferation rather than apopt~sis.'~.'~ Moreover, other membrane receptors known to be involved in apoptosis induction in certain cell types mediate cell proliferation in others. These receptors include the T-and B-cell antigen receptor^,'^.^' CD30," Fad APO-l,'2-34 and the receptors for TNF.' Thus, this dual character of receptor signalling is a common feature of these molecules, including CD43.
Taken together, stem cells, as well as differentiated myeloid cells and mature lymphocytes' do not respond to CD43-mediated stimulation by apoptosis. Therefore, it appears that there is a relatively narrow window within the differentiation pathway of stem cells toward mature hematopoietic cells, in which HPCs are sensitive to apoptosis triggered via CD43. This suggests that CD43-mediated cell death may represent a potent negative regulatory mechanism controlling HPC proliferation. In vivo, this mechanism may be initiated, eg, by interactions of HPCs with the bone marrow stromal cells expressing an unidentified CD43 ligand. Although the existence of such a mechanism still remains to be shown, recent experiments with transgenic mice indicate that CD43 is somehow involved in the in vivo regulation of cell survival. In these animals, de novo expression of this molecule on B cells that are normally CD43-has been shown to be associated with their decreased susceptibility to apoptosis.'s This is seemingly in contradiction with the apoptosis-initiating role of CD43 in HPCs. However, as already noted, signalling via receptors involved in the regulation of apoptosis may induce different cellular responses, depending on the particular cell type and cell stimulation conditions. Therefore, even though the circumstances under which CD43 is engaged in vivo are currently unknown, these findings indicate that CD43 may function as an in vivo regulator of apoptosis, potentially playing an important role in the homeostasis of hematopoietic cell production.
